Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors
Why invest in ZLD?
Zelda Therapeutics Ltd: THE INVESTMENT CASE

Zelda's Stewart Washer discussed medical cannabis trials with investors at Proactive's CEO Sessions

Stewart Washer at Proactive's CEO Sessions this week.
Zelda's Stewart Washer at Proactive's CEO Sessions
INVESTMENT OVERVIEW: ZLD The Big Picture
Stewart Washer, executive director, presenting at Proactive's CEO Sessions

Zelda Therapeutics Ltd's (ASX:ZLD) executive director, Stewart Washer, joined Proactive's CEO Sessions in Melbourne and Sydney this week.

Zelda is developing a range of cannabinoid-based formulations to treat medical conditions.

WATCH NOW: Zelda Therapeutics' Dr Stewart Washer presents at Proactive's CEO Sessions

ACCESS THE FULL PRESENTATION HERE

View full ZLD profile View Profile

Zelda Therapeutics Ltd Timeline

Related Articles

test tubes
January 22 2018
Under former chief executive Peter George and his successor Shaun Chilton, it has been transformed via a series of well-judged, quickly integrated and, crucially, cash generative acquisitions
mri scanner
January 31 2018
It is actively supporting the hunt for breakthrough treatments for Alzheimer’s, Parkinson’s, Huntingdon’s and multiple sclerosis
blood cells
October 04 2017
The two parts of the business - the commercial arm and research function - appear to be firing on all cylinders

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use